Drug intelligence / Profile preview

atomoxetine + fesoterodine

Development stage: Unknown
Lead developer: Brigham and Women's Hospital
Modality: Small Molecules
Administration: Oral

Overview

DAW1033B2 is a combination drug consisting of atomoxetine (a norepinephrine reuptake inhibitor) and fesoterodine (an extended-release antimuscarinic drug). It is being investigated for the treatment of obstructive sleep apnea (OSA). The drug works by targeting the reduction in upper airway dilator muscle activity that occurs at sleep onset in OSA patients, which leads to increased collapsibility of the upper airway compared to normal subjects. By partially restoring pharyngeal muscle activity during sleep, DAW1033B2 aims to reduce OSA severity.

Targets

mAChR (Muscarinic acetylcholine receptors)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on atomoxetine + fesoterodine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atomoxetine + fesoterodine.

Explore the full profile